PubMed:32522282 / 1302-2613 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T21 27-35 GO:0007565 denotes pregnant
T22 51-60 GO:0007565 denotes pregnancy
T23 156-164 GO:0042696 denotes menarche
T24 194-206 GO:0042703 denotes menstruation
T25 319-323 CHEBI:17544 denotes FiO2
T26 319-323 CHEBI:17544 denotes FiO2
T27 368-380 CHEBI:28619 denotes azithromycin
T28 368-380 CHEBI:28619 denotes azithromycin
T29 368-380 DG_6 denotes azithromycin
T30 384-402 CHEBI:5801 denotes hydroxychloroquine
T31 384-402 CHEBI:5801 denotes hydroxychloroquine
T32 384-402 DG_20 denotes hydroxychloroquine
T33 426-433 CHEBI:15854 denotes quinine
T34 426-433 CHEBI:15854 denotes quinine
T35 437-438 CHEBI:51231 denotes 4
T36 437-438 CHEBI:51231 denotes 4
T37 438-439 CHEBI:86228 denotes -
T38 438-439 CHEBI:86228 denotes -
T39 439-453 CHEBI:36709 denotes aminoquinoline
T40 439-453 CHEBI:36709 denotes aminoquinoline
T41 479-486 GO:0007605 denotes hearing
T42 534-540 GO:0007601 denotes Visual
T43 580-585 UBERON:0002107 denotes liver
T44 651-667 UBERON:0001555 denotes gastrointestinal
T45 669-681 UBERON:0001016 denotes neurological
T46 785-792 UBERON:0000948 denotes cardiac
T47 915-922 CHEBI:4551 denotes digoxin
T48 915-922 CHEBI:4551 denotes digoxin
T49 926-933 CHEBI:17234 denotes Glucose
T50 926-933 CHEBI:17234 denotes Glucose
T51 933-936 CHEBI:14314 denotes -6-
T52 933-936 CHEBI:14314 denotes -6-
T53 936-945 CHEBI:18367 denotes phosphate
T54 936-945 CHEBI:18367 denotes phosphate
T55 1000-1005 UBERON:0000178 denotes Blood
T56 1006-1013 CHEBI:17234 denotes glucose
T57 1006-1013 CHEBI:17234 denotes glucose
T58 1212-1217 CHEBI:16933 denotes ergot
T59 1212-1217 CHEBI:16933 denotes ergot
T60 1218-1227 CHEBI:23943 denotes alkaloids
T61 1218-1227 CHEBI:23943 denotes alkaloids
T62 1266-1273 CHEBI:4551 denotes digoxin
T63 1266-1273 CHEBI:4551 denotes digoxin

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T2 580-585 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T3 926-933 Body_part denotes Glucose http://purl.org/sig/ont/fma/fma82743
T4 1000-1005 Body_part denotes Blood http://purl.org/sig/ont/fma/fma9670
T5 1006-1013 Body_part denotes glucose http://purl.org/sig/ont/fma/fma82743
T6 1073-1079 Body_part denotes mental http://purl.org/sig/ont/fma/fma264279

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T2 580-585 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T3 1000-1005 Body_part denotes Blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T6 357-364 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T7 406-422 Disease denotes hypersensitivity http://purl.obolibrary.org/obo/MONDO_0000605|http://purl.obolibrary.org/obo/MONDO_0005271
T9 479-491 Disease denotes hearing loss http://purl.obolibrary.org/obo/MONDO_0005365
T10 494-503 Disease denotes Psoriasis http://purl.obolibrary.org/obo/MONDO_0005083
T11 506-517 Disease denotes Retinopathy http://purl.obolibrary.org/obo/MONDO_0005283
T12 580-594 Disease denotes liver diseases http://purl.obolibrary.org/obo/MONDO_0005154
T13 606-616 Disease denotes amoebiasis http://purl.obolibrary.org/obo/MONDO_0005644
T14 686-709 Disease denotes hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T15 793-813 Disease denotes conduction disorders http://purl.obolibrary.org/obo/MONDO_0007264
T16 814-825 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T17 880-897 Disease denotes Myasthenia gravis http://purl.obolibrary.org/obo/MONDO_0009688
T18 926-970 Disease denotes Glucose-6-phosphate dehydrogenase deficiency http://purl.obolibrary.org/obo/MONDO_0005775
T19 973-982 Disease denotes Porphyria http://purl.obolibrary.org/obo/MONDO_0019142|http://purl.obolibrary.org/obo/MONDO_0037939
T21 985-998 Disease denotes Hypoglycaemia http://purl.obolibrary.org/obo/MONDO_0004946
T22 1073-1087 Disease denotes mental illness http://purl.obolibrary.org/obo/MONDO_0002025

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T12 61-65 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T13 541-546 http://purl.obolibrary.org/obo/UBERON_0007688 denotes field
T14 580-585 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T15 580-585 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T16 742-744 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T17 873-875 http://purl.obolibrary.org/obo/CLO_0007874 denotes ms
T18 1000-1005 http://purl.obolibrary.org/obo/UBERON_0000178 denotes Blood
T19 1000-1005 http://www.ebi.ac.uk/efo/EFO_0000296 denotes Blood

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T8 368-380 Chemical denotes azithromycin http://purl.obolibrary.org/obo/CHEBI_2955
T9 384-402 Chemical denotes hydroxychloroquine http://purl.obolibrary.org/obo/CHEBI_5801
T10 426-433 Chemical denotes quinine http://purl.obolibrary.org/obo/CHEBI_137041|http://purl.obolibrary.org/obo/CHEBI_15854
T12 439-453 Chemical denotes aminoquinoline http://purl.obolibrary.org/obo/CHEBI_36709
T13 915-922 Chemical denotes digoxin http://purl.obolibrary.org/obo/CHEBI_145795|http://purl.obolibrary.org/obo/CHEBI_4551
T15 926-933 Chemical denotes Glucose http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167|http://purl.obolibrary.org/obo/CHEBI_42758
T18 936-945 Chemical denotes phosphate http://purl.obolibrary.org/obo/CHEBI_18367|http://purl.obolibrary.org/obo/CHEBI_26020|http://purl.obolibrary.org/obo/CHEBI_35780|http://purl.obolibrary.org/obo/CHEBI_43474
T22 1006-1013 Chemical denotes glucose http://purl.obolibrary.org/obo/CHEBI_17234|http://purl.obolibrary.org/obo/CHEBI_4167
T24 1212-1227 Chemical denotes ergot alkaloids http://purl.obolibrary.org/obo/CHEBI_23943
T25 1218-1227 Chemical denotes alkaloids http://purl.obolibrary.org/obo/CHEBI_22315
T26 1266-1273 Chemical denotes digoxin http://purl.obolibrary.org/obo/CHEBI_145795|http://purl.obolibrary.org/obo/CHEBI_4551

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 357-364 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T2 406-422 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T3 479-491 Phenotype denotes hearing loss http://purl.obolibrary.org/obo/HP_0000365
T4 494-503 Phenotype denotes Psoriasis http://purl.obolibrary.org/obo/HP_0003765
T5 506-517 Phenotype denotes Retinopathy http://purl.obolibrary.org/obo/HP_0000488
T6 580-594 Phenotype denotes liver diseases http://purl.obolibrary.org/obo/HP_0001392
T7 814-825 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T8 829-851 Phenotype denotes prolonged QTc interval http://purl.obolibrary.org/obo/HP_0005184
T9 880-890 Phenotype denotes Myasthenia http://purl.obolibrary.org/obo/HP_0003473
T10 985-998 Phenotype denotes Hypoglycaemia http://purl.obolibrary.org/obo/HP_0001943

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T2 156-164 http://purl.obolibrary.org/obo/GO_0042696 denotes menarche
T3 194-206 http://purl.obolibrary.org/obo/GO_0042703 denotes menstruation
T4 406-422 http://purl.obolibrary.org/obo/GO_0002524 denotes hypersensitivity
T5 479-486 http://purl.obolibrary.org/obo/GO_0007605 denotes hearing
T6 736-740 http://purl.obolibrary.org/obo/GO_0005006 denotes eGFR
T7 785-803 http://purl.obolibrary.org/obo/GO_0061337 denotes cardiac conduction

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T11 0-1311 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 357-364 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T2 406-422 Phenotype denotes hypersensitivity http://purl.obolibrary.org/obo/HP_0041092
T3 479-491 Phenotype denotes hearing loss http://purl.obolibrary.org/obo/HP_0000365
T4 494-503 Phenotype denotes Psoriasis http://purl.obolibrary.org/obo/HP_0003765
T5 506-517 Phenotype denotes Retinopathy http://purl.obolibrary.org/obo/HP_0000488
T6 580-594 Phenotype denotes liver diseases http://purl.obolibrary.org/obo/HP_0001392
T7 814-825 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T8 829-851 Phenotype denotes prolonged QTc interval http://purl.obolibrary.org/obo/HP_0005184
T9 880-890 Phenotype denotes Myasthenia http://purl.obolibrary.org/obo/HP_0003473
T10 985-998 Phenotype denotes Hypoglycaemia http://purl.obolibrary.org/obo/HP_0001943

Inflammaging

Id Subject Object Predicate Lexical cue
T11 0-1311 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.
T11 0-1311 Sentence denotes Fertile women* must not be pregnant, i.e. negative pregnancy test must be available at inclusion • Informed consent signed by the patient *Defined as after menarche and until postmenopausal (no menstruation for 12 months) Exclusion criteria: • At the time of recruitment, the patient uses >5 LO2/min (equivalent to 40% FiO2 if measured) • Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to quinine or 4-aminoquinoline derivatives • Neurogenic hearing loss • Psoriasis • Retinopathy • Maculopathy • Visual field changes • Breastfeeding • Severe liver diseases other than amoebiasis (INR> 1.5 spontaneously) • Severe gastrointestinal, neurological and hematological disorders (investigator-assessed) • eGFR <45 ml/min/1.73 m2 • Clinically significant cardiac conduction disorders/arrhythmias or prolonged QTc interval (QTc (f) of> 480/470 ms). • Myasthenia gravis • Treatment with digoxin* • Glucose-6-phosphate dehydrogenase deficiency • Porphyria • Hypoglycaemia (Blood glucose at any time since hospitalization of <3.0 mmol/L) • Severe mental illness which significantly impedes cooperation • Severe linguistic problems that significantly hinder cooperation • Treatment with ergot alkaloids *The patient must not be treated with digoxin for the duration of the intervention.